ProfileGDS5678 / 1436526_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 66% 67% 71% 66% 66% 65% 66% 66% 67% 67% 66% 67% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1139267
GSM967853U87-EV human glioblastoma xenograft - Control 23.9919866
GSM967854U87-EV human glioblastoma xenograft - Control 34.0311867
GSM967855U87-EV human glioblastoma xenograft - Control 44.5003371
GSM967856U87-EV human glioblastoma xenograft - Control 53.9800966
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0187766
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9645565
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0090366
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9924466
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1150967
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0447367
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9407866
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.05467
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1427768